Are psychedelic drug treatments seeing a comeback in psychiatry?

Progress in Neurology and Psychiatry

Volumn 12, Issue 8, 2008, Pages 5-10

  Sessa, Benjamin St John ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; IBOGAINE; KETAMINE; LYSERGIDE; MESCALINE; N,N DIMETHYLTRYPTAMINE; PLACEBO; PSILOCYBINE; PSYCHEDELIC AGENT; RECREATIONAL DRUG;

ADDICTION; ADJUVANT THERAPY; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; ARTICLE; CANCER PAIN; CLINICAL EFFECTIVENESS; CLINICAL MEDICINE; CLINICAL TRIAL; DEPRESSION; DRUG ABUSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; HEROIN DEPENDENCE; HISTORY OF MEDICINE; HUMAN; MENTAL DISEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPIATE ADDICTION; PERCEPTION DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; PSYCHOTHERAPY; SIDE EFFECT; VISION;

EID: 58049088995     PISSN: 13677543     EISSN: None     Source Type: Journal    
DOI: 10.1002/pnp.94     Document Type: Article

References (37)

1. Sessa B. Is it time to revisit the role of psychedelic drugs in enhancing human creativity? J Psychophormacol 2008: In Press.
2. Schultes E, Hofmann A, Ratsch C. Plants of the Gods. Rochester, Vermont: Healing Arts Press 1998:pp9-19.
3. Hoffman A. LSD:My Problem Child. McGraw-Hill Book Company 1980:pp35-52.
4. Grinspoon L, Bakalar B. Therapeutic uses. In: Psychedelic Drugs Reconsidered. New York: The Lindsmith Center, 1997:pp192-237.
5. Malleson N.Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 1971;118:229-30.
6. Grof S. The principle of LSD psychotherapy. In: LSD Psychotherpy Florida:Multidisciplinary Association for Psychedelic Studies, 2001:pp123-47.
7. Grob C. Psychiatric research with hallucinogens:What have we learned? The Yearbook for Ethnomedicine and the Study of Consciousness, Issue 3, 1994.
8. Sessa B. Can psychedelics have a role in psychiatry again? Br J Psychiatry 2005;186:457-8.
9. Vollenweider FX, Gamma A, Liechti M, et al. Psychological and cardiovascular effects and short-term sequalae of MDMA ('ecstasy') in MDMA naive healthy volunteers. Neuropsychopharmacology 1998;19:241-51.
10. Greer GR, Tolbert R.A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 1998;30(4):371-9.
11. Bouso JC.Using MDMA in the treatment of post-traumatic stress disorder.In:Ecstasy: The Complete Guide. Julie Holland,ed.Vermont, Rochester:Park Street Press, 2001:pp248-61.
12. Greer G,Tolbert R. The therapeutic use of MDMA.In: Ecstasy:The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. SJ Peroutka, ed. Holland: Kluwer, 1990.
13. Cami J, Farre M, Mas M, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine ('ecstasy'): psychomotor performance and subjective effects. J Clin Psychopharmacol 2000;20:455-66.
14. Greer GR, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18(4):319-27.
15. Holland J. The Legal Status of MDMA around the World. In: Ecstasy:A Complete Guide. Julie Holland, ed. 2001.Vermont: Park Street Press, 2001:Chapter 10.
16. Sessa B. Is there a role for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 2007;21(2):220-4.
17. Strassman RJ. Human hallucinogenic drug research: regulatory, clinical, and scientific issues. NIDA Res Monogr 1994;146:92-123.
18. Cohen S. Lysergic acid diethylamide: side effects and complications. J Nervous and Mental Disorders 1960;130:30-40.
19. Halpern J, Pope H. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003;69(2):109-19.
20. Fantegrossi WE, Woods JH, Winmger G. Transient reinforcing effects of phenylisopropylamine and indoealkylamine hallucinogens in rhesus monkeys. Behavioural Pharmacol 2004;15:149-57.
21. Vollenweider FX, Gucker P, Schönbächler R, et al. Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at the 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine.
22. Nutt DJ, Blakemore C, et al. The Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007;369:1047-53.
23. Nichols DE. Hallucinogens. Pharmacol Ther 2004;101(2):131-81.
24. Halser F, Grimberg U, Benz, et al.Acute psychological and physiological effects of psilocybin in healthy humans: A double blind, placebo-controlled dose-effect study. Psychopharmacology 2004;172:145-56.
25. Protocol at: www.maps.org/research/mdma/ptsd_study/protocol/ protocol051606.pdf
26. Protocol available at:www.maps.org/mdma/swissptsd/protocol011806.pdf
27. Protocol available at:www.canceranxietystudy.org
28. Protocol at:www.maps.org/research/lsd/swisslsd/LDA1010707.pdf
29. Protocol available at:www.maps.org/ibogaine/iboprotocol70706.pdf
30. Details can be found at:www.heffter.org/pages/research.html
31. Protocol at:www.maps.org/research/mdma/canceranxiety/irb-protocol/
32. Details can be found at:www.clusterbusters.org
33. Moreno FA,Wiegand CB, Taitano EK, et al. Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006;67:1735-40.
34. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT):A Review of the Results of Ten Years of Research. J Psychoactive Drugs 1997;29(2):165-83.
35. Krupitsky,EM,Burakof AM,Dunaevsky IV,et al.Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 2007;39(1):13-9.
36. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (online edition):July 11, 2006.
37. Strassman R. DMT:The Spirit Molecule. Rochester,Vermont: Park Street Press, 2001:pp89-98.